

SUPPLEMENTARY MATERIAL

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study

Diamant Thaçi¹, Andrea Bauer², Ralph von Kiedrowski³, Florian Schenck⁴, Konstantin Ertner⁵, Sophie Möller⁶, Anja Fait⁷, Mike Bastian⁷, Matthias Augustin⁸

¹*Institute and Comprehensive Centre for Inflammatory Medicine, University of Luebeck, Luebeck, Germany*

²*Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany*

³*Company for Medical Study & Service Selters GmbH and Dermatology Practice Dr von Kiedrowski, Selters (Westerwald), Germany*

⁴*Hautärzte Zentrum Hannover, Hannover, Germany*

⁵*Hautarztpraxis Dr Ertner, Nürnberg, Germany*

⁶*Sanofi, Berlin, Germany*

⁷*Sanofi, Frankfurt, Germany*

⁸*Institute of Health Care Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

Corresponding author:

Diamant Thaçi, Institute and Comprehensive Centre for Inflammatory Medicine, University of Luebeck, Ratzeburger Alee 160, 23538 Luebeck, Germany

Phone: +49 451 500 41600; Email: Diamant.Thaci@uksh.de

Supplementary Table 1: Family history of type 2 inflammatory diseases (*n* = 817)

Manifestation, %	Yes	No	Missing/unknown
Allergic rhinitis	45.8	38.8	15.4
Atopic dermatitis	40.4	46.3	13.3
Asthma	26.3	59.9	13.8
Dust mite allergy	25.5	45.4	29.1
Food allergy	24.9	50.3	24.8
Nasal polyps	13.6	50.9	35.5

AD, atopic dermatitis.

Supplementary Table 2: Burden of disease (hospitalisations, exacerbations, and treatments) at baseline (*n* = 817)

Outcome	Mean	SD	Median	IQR	<i>n</i>
Number of exacerbations experienced in the past 12 months	6.1	9.1	4.0	2.0–8.0	813
Number of inpatient nights in the hospital in the past 24 months for the treatment of AD	2.1	6.4	0	0–0	817
Number of days in the day hospital in the past 24 months for the treatment of AD	0.8	4.9	0	0–0	816
Number of visits to the hospital outpatient department in the past 24 months for the treatment of AD	1.1	3.5	0	0–0	817
Number of days receiving UV therapy in the past 24 months	5.3	14.6	0	0–1.0	814


AD, atopic dermatitis; IQR, interquartile range; *n*, number of patients; SD, standard deviation; UV ultraviolet.

Supplementary Table 3: Patient questionnaire at baseline: effort and financial burden due to AD (*n* = 817)

Question	Mean	SD	Median	IQR	<i>n</i>
In the last 12 months, how many times did you visit a physician because of your AD?	8.2	7.6	6.0	4.0–10.0	709
How much money (€) do you spend every month in addition to the prescribed medications for the treatment of your AD?	56.96	58.22	40.00	20.0–70.0	718

AD, atopic dermatitis; IQR, interquartile range; *n*, number of patients.

Supplementary Fig. 1: Age at baseline according to sex (categorical) ($n = 817$)




n , number of patients.

Supplementary Fig. 2 A) clinical eligibility criteria for systemic treatment⁶; B) recruited PROLEAD patients fulfilling checklist criteria (n = 817)

A)

Clinical eligibility criteria for systemic treatment		Yes	No
A: Relevant objective severity	Is present, since <u>at least one</u> of the following criteria is fulfilled:	0	
	• PGA of severity is at least three on the five-point scale, <u>or</u>	0	0
	• EASI > 15 <u>or</u>	0	0
	• SCORAD >40/ oSCORAD >20 <u>or</u>	0	0
	• Treatment-refractory affection of >10% of BSA <u>or</u>	0	0
	• Treatment-refractory eczema in sensitive/visible areas, <u>or</u>	0	0
	• High-frequency of relapses (>10/year) with current treatment, <u>or</u>	0	0
B: Relevant subjective burden	Is present, since <u>at least one</u> of the following criteria is fulfilled:	0	
	• DLQI >10, <u>or</u>	0	0
	• Pruritus >6 (on VAS or NRS ranging from 0–10) <u>or</u>	0	0
	○ Relevant sleep disturbance at night due to eczema/pruritus	0	0
C: Lack of treatment response	All other approaches except systemic treatment are insufficient, since <u>at least one</u> of the following criteria is fulfilled:	0	
	• No satisfactory response to topical or phototherapy <u>or</u>	0	0
	• No expectation of success with topical measures alone <u>or</u>	0	0
	Patient has already received one indicated systemic treatment unsuccessfully	0	0
	• Contra-indication/no response/loss of efficacy/adverse events		

B)



BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, eczema area and severity index; *n*, number of patients; NRS, numeric rating scale; oSCORAD, objective-SCORAD; PGA, physician's global assessment; SCORAD, scoring AD; VAS, visual analogue scale.